For example, increased sensitivity to proapoptotic C6-ceramide can be accomplished in leukemia and colorectal cancer cells via the inclusion of either tamoxifen, tariquidar, or zosuquidar, first- and third-generation P-gp antagonists (Table 1C) [158]. Here, PGP is linked to leukemia.